The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Clinical Features and Outcome of Patients With IRAK-4 and MyD88 Deficiency
Open accessAbstract
Autosomal recessive interleukin-1 receptor-associated kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity. We documented the clinical features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries.The clinical features of IRAK-4 and MyD88 deficiency were indistinguishable. There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow. Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively. The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%). P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, respectively, in 13 and 13 patients, respectively). Systemic signs of inflammation were usually weak or delayed. The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients. Multiple or recurrent invasive infections were observed in most survivors (n = 36/50, 72%).Clinical outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease. However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, respectively. Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter.IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation. Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever. Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Toll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328
Pyogenic Bacterial Infections in Humans with MyD88 Deficiency
von Bernuth, H., Picard, C., Jin, Z., Pankla, R., Xiao, H., Ku, C.-L., Chrabieh, M., Mustapha, I. B., Ghandil, P., Camcioglu, Y., et al. (2008) · Science · doi:10.1126/science.1158298 · Cited by 1,287
Self-citationTLR3 Deficiency in Patients with Herpes Simplex Encephalitis
Zhang, S.-Y., Jouanguy, E., Ugolini, S., Smahi, A., Elain, G., Romero, P., Segal, D., Sancho-Shimizu, V., Lorenzo, L., Puel, A., et al. (2007) · Science · doi:10.1126/science.1139522 · Cited by 1,057
Self-citationDominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,048
Self-citationHuman C-reactive protein: expression, structure, and function
Volanakis, J. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00042-6 · Cited by 926
IL‐1, IL‐18, and IL‐33 families of cytokines
Arend, W. P., Palmer, G., & Gabay, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00624.x · Cited by 912
Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency
Picard, C., Puel, A., Bonnet, M., Ku, C.-L., Bustamante, J., Yang, K., Soudais, C., Dupuis, S., Feinberg, J., Fieschi, C., et al. (2003) · Science · doi:10.1126/science.1081902 · Cited by 826
Self-citationThe neonatal blood count in health and disease.I. Reference values for neutrophilic cells
Manroe, B. L., Weinberg, A. G., Rosenfeld, C. R., & Browne, R. (1979) · The Journal of Pediatrics · doi:10.1016/s0022-3476(79)80096-7 · Cited by 780
Combined Immunodeficiency Associated with DOCK8 Mutations
Zhang, Q., Davis, J. C., Lamborn, I. T., Freeman, A. F., Jing, H., Favreau, A. J., Matthews, H. F., Davis, J., Turner, M. L., Uzel, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905506 · Cited by 742
Self-citation
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Hsu, J. T., Keller, M., Kobrynski, L. J., Komarow, H. D., Mazer, B., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.049 · Cited by 791
Self-citationNeutrophils: Between Host Defence, Immune Modulation, and Tissue Injury
Kruger, P., Saffarzadeh, M., Weber, A. N. R., Rieber, N., Radsak, M., von Bernuth, H., Benarafa, C., Roos, D., Skokowa, J., & Hartl, D. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004651 · Cited by 657
Self-citationToll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Human genetic susceptibility to infectious disease
Chapman, S. J., & Hill, A. V. S. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3114 · Cited by 499
Pathogenesis and Pathophysiology of Pneumococcal Meningitis
Mook-Kanamori, B. B., Geldhoff, M., van der Poll, T., & van de Beek, D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-11 · Cited by 492
The type I interferonopathies: 10 years on
Crow, Y. J., & Stetson, D. B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00633-9 · Cited by 489
Boisson, B., Laplantine, E., Prando, C., Giliani, S., Israelsson, E., Xu, Z., Abhyankar, A., Israël, L., Trevejo-Nunez, G., Bogunovic, D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2457 · Cited by 474
Self-citationImmunity against Staphylococcus aureus cutaneous infections
Miller, L. S., & Cho, J. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3010 · Cited by 434
Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or IκBα Deficiency
Picard, C., Casanova, J.-L., & Puel, A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-11 · Cited by 394
Self-citationGenetic variation in Toll-like receptors and disease susceptibility
Netea, M. G., Wijmenga, C., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2284 · Cited by 376
Casanova, J.-L., Abel, L., & Quintana-Murci, L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101335 · Cited by 366
Self-citationIntegration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Chandesris, M.-O., Melki, I., Natividad, A., Puel, A., Fieschi, C., Yun, L., Thumerelle, C., Oksenhendler, E., Boutboul, D., Thomas, C., et al. (2012) · Medicine · doi:10.1097/md.0b013e31825f95b9 · Cited by 335
Self-citationImmunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
Simmons, J. D., Stein, C. M., Seshadri, C., Campo, M., Alter, G., Fortune, S., Schurr, E., Wallis, R. S., Churchyard, G., Mayanja-Kizza, H., et al. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0025-3 · Cited by 314
Community-acquired bacterial meningitis
van de Beek, D., Brouwer, M., Hasbun, R., Koedel, U., Whitney, C. G., & Wijdicks, E. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.74 · Cited by 312
Guo, Y., Audry, M., Ciancanelli, M., Alsina, L., Azevedo, J., Herman, M., Anguiano, E., Sancho-Shimizu, V., Lorenzo, L., Pauwels, E., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101568 · Cited by 309
Self-citationBoisson, B., Laplantine, E., Dobbs, K., Cobat, A., Tarantino, N., Hazen, M., Lidov, H. G. W., Hopkins, G., Du, L., Belkadi, A., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141130 · Cited by 295
Self-citationBeyond pattern recognition: five immune checkpoints for scaling the microbial threat
Blander, J. M., & Sander, L. E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3167 · Cited by 290
Herman, M., Ciancanelli, M., Ou, Y.-H., Lorenzo, L., Klaudel-Dreszler, M., Pauwels, E., Sancho-Shimizu, V., Pérez de Diego, R., Abhyankar, A., Israelsson, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111316 · Cited by 278
Self-citationPseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Cloutier, N., Allaeys, I., Marcoux, G., Machlus, K. R., Mailhot, B., Zufferey, A., Levesque, T., Becker, Y., Tessandier, N., Melki, I., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720553115 · Cited by 219
Incomplete penetrance in primary immunodeficiency: a skeleton in the closet
Gruber, C., & Bogunovic, D. (2020) · Human Genetics · doi:10.1007/s00439-020-02131-9 · Cited by 97
Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex
Zaro, B. W., Vinogradova, E. V., Lazar, D. C., Blewett, M. M., Suciu, R. M., Takaya, J., Studer, S., de la Torre, J. C., Casanova, J.-L., Cravatt, B. F., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801627 · Cited by 68
Self-citationInvestigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis
Wiese, M. D., Manning-Bennett, A. T., & Abuhelwa, A. Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1752660 · Cited by 58
Metadata
- Authors
- Picard, C., von Bernuth, H., Ghandil, P., Chrabieh, M., Levy, O., Arkwright, P. D., McDonald, D., Geha, R. S., Takada, H., Krause, J. C., Creech, C. B., Ku, C.-L., Ehl, S., Maródi, L., Al-Muhsen, S., Al-Hajjar, S., Al-Ghonaium, A., Day-Good, N. K., Holland, S. M., Gallin, J. I., Chapel, H., Speert, D. P., Rodriguez-Gallego, C., Colino, E., Garty, B.-Z., Roifman, C., Hara, T., Yoshikawa, H., Nonoyama, S., Domachowske, J., Issekutz, A. C., Tang, M., Smart, J., Zitnik, S. E., Hoarau, C., Kumararatne, D. S., Thrasher, A. J., Davies, E. G., Bethune, C., Sirvent, N., de Ricaud, D., Camcioglu, Y., Vasconcelos, J., Guedes, M., Vitor, A. B., Rodrigo, C., Almazán, F., Méndez, M., Aróstegui, J. I., Alsina, L., Fortuny, C., Reichenbach, J., Verbsky, J. W., Bossuyt, X., Doffinger, R., Abel, L., Puel, A., & Casanova, J.-L.
- Venue
- Medicine
- Published
- 2010-11
- Volume
- 89
- Issue
- 6
- Pages
- 403-425
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2087098495
- Cited by
- 426
- References
- 44
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.